Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

• Published in: Intensive care medicine Vol. 46; no. 7; pp. 1425 - 1437
• Main Authors: François, Bruno, Wittebole, Xavier, Ferrer, Ricard, Mira, Jean-Paul, Dugernier, Thierry, Gibot, Sébastien, Derive, Marc, Olivier, Aurélie, Cuvier, Valérie, Witte, Stephan, Pickkers, Peter, Vandenhende, François, Garaud, Jean-Jacques, Sánchez, Miguel, Salcedo-Magguilli, Margarita, Laterre, Pierre-François
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2020; Springer; Springer Nature B.V
• Subjects: Anesthesiology; Animal models; Animals; Antibodies; Biological products; Biomarkers; Clinical trials; Critical Care Medicine; Double-Blind Method; Drug dosages; Emergency Medicine; Health aspects; Humans; Immunologic Factors; Intensive; Intensive care; Medicine; Medicine & Public Health; Original; Pain Medicine; Patients; Pediatrics; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pneumology/Respiratory System; Randomization; Safety; Sepsis; Septic shock; Shock, Septic - drug therapy; Treatment Outcome; Belgium; France; Canada; TREM-1; Septic shock; LR12; Nangibotide

Purpose Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host–pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodyna...